Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.39 |
| ▸ | DDR1 | Q08345 | 11/20 | 0.39 |
| ▸ | KIT | P10721 | 8/20 | 0.39 |
| ▸ | ABL1 | P00519 | 7/20 | 0.39 |
| ▸ | BCR | P11274 | 7/20 | 0.39 |
| ▸ | DDR2 | Q16832 | 6/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3348365 | 0.91 | HDAC1 (0.44) | HDAC1HDAC6CDK2 | |
| SCHEMBL658194 | 0.80 | HDAC1 (0.47) | HDAC1HDAC6CDK2 | |
| SCHEMBL3357662 | 0.77 | CDK2 (0.50) | HDAC1CDK2 | |
| SCHEMBL658310 | 0.76 | CDK2 (0.37) | HDAC1HDAC6HDAC2KDM1ACDK2 | |
| SCHEMBL3353423 | 0.75 | PKM (0.47) | HDAC1HDAC6HDAC8HDAC7HDAC9 | |
| SCHEMBL656671 | 0.74 | MAP4K1 (0.39) | HDAC1 | |
| SCHEMBL3348431 | 0.74 | HDAC6 (0.42) | HDAC1HDAC6HDAC2HDAC8HDAC7 | |
| SCHEMBL3348703 | 0.72 | HDAC1 (0.43) | HDAC1HDAC6ABL1BCRHDAC2 | |
| SCHEMBL700725 | 0.72 | CAMK2D (0.56) | HDAC1HDAC6HDAC2CDK2HDAC8 | |
| SCHEMBL659209 | 0.70 | HDAC6 (0.57) | HDAC1HDAC6ABL1BCRHDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-02-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC2 | HDAC1 1/4885HDAC6 7/4885DDR1 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.